Fresenius Kabi launches generic sugammadex prefilled syringe in US
I'm LongbridgeAI, I can summarize articles.Fresenius Kabi has launched an FDA-approved generic sugammadex injection in the US, available in Simplist prefilled syringes. This move follows the expiry of Merck’s Bridion exclusivity in July 2026, introducing generic competition to the market. The product targets operating rooms with a single-dose 200 mg/2 mL format to streamline medication handling. Fresenius Kabi will handle formulation, filling, and packaging domestically, supporting US supply-chain resilience.
- Fresenius unit Fresenius Kabi launched an FDA-approved generic sugammadex injection in the US in Simplist ready-to-administer prefilled syringes. * Launch follows expiry of Merck’s Bridion exclusivity in July 2026, opening the US market to generic competition. * Product targets operating rooms, aiming to streamline medication handling with a single-dose 200 mg/2 mL prefilled syringe format. * Fresenius Kabi will formulate, fill, and package the product in the US, supporting supply-chain resilience and domestic manufacturing capacity. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via Business Wire (Ref. ID: 202609031700BIZWIRE_USPR_____20260903_BW952886) on September 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)